Mechanisms of action and resistance of histone deacetylase inhibitors (HDACIs) are not well understood. A gene expression analysis performed in a phase I trial of vorinostat in leukemia indicated that overexpression of genes involved in antioxidant defense was associated with clinical resistance. We hypothesized that non-epigenetic mechanisms may be involved in resistance to HDACI therapy 
Introduction
Histone deacetylase inhibitors (HDACIs) are a class of agents with the capacity to induce acetylation of histone and non-histone proteins. 1 HDACIs have been intensively investigated in preclinical models as well as in clinical trials for a variety of malignancies. Various mechanisms of action have been proposed for the anticancer activity of HDACIs. Early work has focused on their effect on gene transcription by inducing permissive histone marks. Other pharmacologic actions include activation of extrinsic and intrinsic apoptotic pathways [2] [3] [4] , induction of cell cycle arrest 5 , autophagic cell death 6 and senescence. 7 Despite these wellcharacterized properties of HDACIs, the precise mechanism of their in vivo activity still remains to be elucidated.
Suberoylanilide hydroxamic acid (vorinostat) is a small molecule inhibitor of class I and II histone deacetylase inhibitor. 1 Vorinostat has significant activity in cutaneous T cell lymphoma. 8, 9 Previous studies have also demonstrated that vorinostat has anti-leukemia-activity in vitro and in rodent models. 5, [10] [11] [12] In a phase I clinical trial, vorinostat was shown to have modest clinical activity in patients with advanced leukemia. 13 A cDNA microarray analysis performed in that trial suggested that a gene signature composed mainly of antioxidants was associated with clinical resistance to vorinostat. Thus, induction of reactive oxygen species (ROS) could be a potential mechanism of vorinostat action whereas increased antioxidant expression may contribute to vorinostat resistance.
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14 Therefore, cells have developed a highly regulated antioxidant defense system to prevent oxidative damage. This cellular defense mechanisms against ROS include redox buffering systems and various antioxidant enzymes, such as glutathione (GSH) generating enzymes including glutamate cysteine ligase (GCL) and glutathione reductase (GSR), glutathione Stransferase (GST), and superoxide dismutase (SOD). 14 Many of these antioxidant enzymes are under control of a transcription factor NF-E2-related factor-2 (Nrf2). 15, 16 Despite previous reports on stimulation of ROS generation by
HDACIs in cancer cells 17, 18 , the source of ROS still remains unclear. Furthermore the role of antioxidants in cellular defense against HDACIs remains to be investigated. Thus, the study of mechanism of HDACI action in the context of ROS generation is important for the design of drug combination strategies to overcome HDACI resistance.
β-phenylethyl isothiocyanate (PEITC) is a natural compound found in cruciferous vegetables. 19 Recent studies have shown that PEITC effectively disables glutathione antioxidant system and selectively kills cancer cells with increased ROS generation. 19, 20 Given the fact that glutathione is the most abundant antioxidant system against ROS stress and that a series of glutathionerelated enzymes were upregulated in leukemia patients who were resistant to vorinostat 13 , we hypothesized that PEITC might enhance the anti-leukemia activity of vorinostat by modulating cellular redox status. The objectives of the study presented here were to determine how HDACIs increase ROS generation
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From in leukemia cells, to characterize the role of Nrf2 and its downstream antioxidant enzymes in protecting cells against HDACI-induced ROS stress, and finally to determine whether combination of an HDACI with PEITC could lead to synergistic cytotoxic effect against leukemia cells. This study provides important information for the understanding of mechanism of action of HDACIs and resistance to this class of compounds.
Materials and methods

Antibodies and reagents
The following antibodies were used for immunoblotting analysis using standard western blotting procedures: SOD2, GST-Pi, GPX1, GCLC and Nrf2 from Santa Cruz (Santa Cruz, CA); β-actin from Sigma (St Louis, MO). PEITC, diphenylene iodonium (DPI), 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolim (MTT) and N-acetylcysteine (NAC) were purchased from Sigma. Vorinostat and MGCD0103 were provided by Merck (Whitehouse, Station, NJ) and MethylGene (Montreal, Quebeck, Canada), respectively.
Cell culture
Human leukemia cells lines (HL60, HL60/LR, U937 and ML1) were cultured at 37°C in an atmosphere of 5% CO 2 in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine.
HL60/C6F cells were maintained in RPMI 1640 medium containing 0.47% glucose, 10% FBS, 50 µg/ml uridine and 1 mM pyruvate. Primary leukemia cells were isolated from peripheral blood samples from patients with AML after proper 
ROS detection
Cellular O 2
-and H 2 O 2 were measured by flow cytometry using hydroethidine (Het) and CM-H2DCF-DA (Invitrogen, Carlsbad, CA), respectively.
After incubation with Het (100 ng/ml) or CM-H2DCF-DA (3 μM) at 37 °C for 1 h, samples were washed with PBS and analyzed with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Data was analyzed using BD Biosciences CellQuest Pro software package.
Real time PCR
Total RNA was extracted using the RNeasy kit (QIAGEN, Valencia, CA)
followed by DNAase (Ambion, Austin, TX) treatment according to manufacturer's instructions. cDNA was prepared using TaqMan Reverse Transcription Reagents (Applied Biosystem, Foster City, CA). 50 ng of cDNA was subjected to quantitative real-time PCR using ABI 7700 sequence detection system and SYBR reagents (Invitrogen, Carlsbad, CA). GAPDH was used as the internal Immunofluorescence and confocal microscopy U937 cells were cytospun, fixed with 3.7% paraformaldehyde and permeabilized with 0.2% Triton-X 100. Cells were incubated with 5% BSA for 1 h at room temperature before incubation with Nrf2 antibody (Santa Cruz, Santa Cruz, CA) at 4 ºC overnight. Alexa Fluor 594 goat-anti-rabbit (Invitrogen, Carlsbad, CA) was added to the samples and incubated at room temperature for 1 h. Slides were washed with PBS, mounted and counterstained with mounting medium with DAPI (Santa Cruz, Santa Cruz, CA). Images were captured with a Nikon Eclipse TE2000 confocal microscope and analyzed with Nikon EZ-C1 software (Nikon, Melville, NY).
Measurement of cellular glutathione
A glutathione assay kit (Cayman Chemical, Ann Arbor, MI) was used to measure total cellular glutathione as described. 19 Briefly, cell extracts were sonicated in phosphate buffer and deproteinated with metaphosphoric acid. The level of total glutathione was detected by measuring the product of glutathionylated DTNB with a UV spectrophotometer at 405 nm. Cellular glutathione contents were calculated using standard curves generated in parallel experiments.
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Nrf2 transfection
A pre-designed pCMV6-XL5 vector containing Nrf2 cDNA (OriGene Technologies, Rockville, MD) was transfected into HEK293 cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells transfected with vector only were used as control. After transfection for 40 hrs, cells were subjected to Western blot analysis to verify Nrf2 protein expression.
Statistical analysis
The statistical significance of differences between two experimental groups was determined by two-tailed Student's t-test. The cytotoxic combination effect of an HDACI with PEITC was calculated using Calcusyn (Biosoft, Ferguson, MO).
Results
Increase of major antioxidants and decrease of ROS in pan-HDACI resistant cell line HL60/LR
A pan-HDACI resistant cell clone HL60/LR has been recently generated by continuous exposure of the AML cell line HL60 to the hydroxamate analog LAQ824. 22 In order to study the molecular mechanisms underlying cellular resistance to an HDACI, we first compared the redox parameters, including major antioxidants and ROS levels, in HL60 and HL60/LR cells. Gene expression of various glutathione-related enzymes was significantly upregulated in HL60/LR cells compared to the parental HL60 cells ( Figure 1A ). These enzymes include glutamate-cysteine ligase (catalytic subunit GCLC and regulatory subunit Figure 1B confirms the increase of GCLC, GST-Pi, GPX1 and SOD2 in HL60/LR cells at the protein level. Nrf2, a master transcription factor that has been shown to control gene expression of GCLC, GPX, GST and SOD 16 was also upregulated at the mRNA and protein levels in HL60/LR cells. Glutathione is the most abundant antioxidant buffer system and the substrate for xenobiotic detoxification enzyme GST-pi. 14 As a result of upregulation of GSH synthesis enzyme GCLC and GSH regeneration enzyme GSR, cellular glutathione level was also found to be elevated in HL60/LR cells 
Vorinostat induces ROS generation through NADPH oxidase activation
Consistent with previous reports of ROS induction by HDACIs, 3 ,18,24 we observed that vorinostat induced early accumulation of ROS in HL60, U937 and ML1 cells ( Figure 1D and data not shown). However, the initial source of ROS remains unclear. It is known that mitochondria respiratory chain and NADPH Oxidase (NOX) are two major sources of ROS generation. 25, 26 To study the source of ROS production induced by vorinostat, we first examined the activity of NOX after vorinostat treatment. As shown in Figure 2A , 
Activation of Nrf2 and increase of antioxidant defense genes induced by vorinostat
To investigate the effect of vorinostat on major antioxidants, U937 cells were exposed to 2 µM vorinostat for 20 hrs and gene expression levels were analyzed by real-time PCR. As shown in Figure 3A , exposure to vorinostat significantly increased gene expression of GCLC, the catalytic enzyme responsible for GSH synthesis. The regulatory subunit GCLM was also increased but to a lesser extent. In addition, GSR, the enzyme responsible for GSH regeneration and GST-Pi, the enzyme that utilizes GSH to detoxify a foreign compound, and SOD1 and SOD2, the enzymes that eliminate O 2 -, were all upregulated. These results strongly suggested that treatment of leukemia cells with vorinostat also induced upregulation of genes responsible for cellular defense against oxidative stress as a secondary response.
It has been suggested that the transcription factor Nrf2 plays a critical role in modulating expression of genes that function as antioxidants, phase II detoxification enzymes, and heat-shock proteins. 15, 16 We also studied the mRNA levels of Nrf2. Nrf2 gene expression was not affected after treatment with vorinostat ( Figure 3A ). It has been shown that in normal physiological state, Nrf2 localizes in the cytoplasm and interacts with Kelch-like ECH-associating protein 1 (Keap1). 
PEITC enhances vorinostat cytotoxicity in myeloid cell lines as well as primary human leukemia cells by modulating cellular redox status
Based on clinical data 13 and results shown here, we postulated that PEITC, a novel compound that has been shown to deplete cellular glutathione 19, 20 , may circumvent resistance to HDACIs and maximize their antileukemia activity. The rationale for our hypothesis is illustrated in Figure 4A . 20 We used a lower concentration of PEITC (2.5 μM) in combination with vorinostat to treat U937 cells. In Figure 4B , flow cytometric analysis We then tested the effect of different sequences of vorinostat/PEITC administration on cell viability. Both U937 and ML1 cells were treated with 2 μM vorinostat and 2.5 μM PEITC concomitantly, or with vorinostat before and after PEITC. Figure 5E shows increase of cell death induced by co-administration of vorinostat and PEITC after 48 hrs compared with single agents alone. We also tested the combination effect using MGCD0103, a non-hydroxamic acid class I specific HDACI 33 , with PEITC. A similar synergistic cytotoxic effect was also observed in several leukemia cell lines (data not shown).
Finally, the effect of vorinostat, PEITC and their combination were tested in primary leukemia cells isolated from 7 AML patients with high blast counts in peripheral blood. As shown in Figure 6A , fresh leukemia cells were treated with 
HDACIs also induce apoptosis, autophagy, cell cycle arrest and senescence. 1 Despite their well-characterized effects in vitro and in vivo, the activity of this class of compounds has been modest in leukemia. We had previously reported a phase I study of vorinostat in patient with advanced leukemias and myelodysplastic syndrome (MDS).
13 Overall 17% patients achieved response.
We detected that increased baseline expression of 17 antioxidant genes correlated with vorinostat resistance. The objectives of this study were to investigate the molecular mechanism of action of HDACIs in the context of ROS generation and the role of antioxidants in resistance to HDACIs. The understanding of mechanisms of resistance to HDACIs will allow development of effective combination strategies to maximize the cytotoxic effect of this class of compounds.
A stable pan HDACI-resistant cell line, HL60/LR, has been generated by culturing HL60 cells under constant selection pressure of the hydroxamic acid analog LAQ824. 22 We first compared the redox status of parental HL60 cells and HL60/LR cells. A series of glutathione (GSH)-related enzymes were significantly upregulated both at the mRNA and protein levels in HL60/LR cells. These included: GCLC, the rate-limiting enzyme for GSH synthesis; GSR, the enzyme The rates of endogenous ROS production and elimination are two major factors that determine overall cellular ROS levels. A combination of two compounds that stimulate endogenous ROS generation and inhibit ROS elimination would be a logical strategy to create severe cellular oxidative stress.
We hypothesized that PEITC, a compound that has been reported to deplete Importantly, PEITC was also able to increase ROS levels and reverse vorinostat resistance in HL60/LR cells.
The cytotoxic effect of the combination was schedule dependent. The effect of vorinostat followed by PEITC incubation was more effective than coadministration of vorinostat plus PEITC, whereas PEITC followed by vorinostat followed by vorinostat, the peak of glutathione conjugation would have occurred before vorinostat-induced upregulation of GSH buffer system. We also tested the activity of the combination in primary AML cells and normal mononuclear cells.
We confirmed the synergistic cytotoxicity effect also in these primary cells.
To analyze whether the findings observed here were specific for vorinostat, we also used MGCD0103, a benzamide that inhibits class I HDACI. Similar synergistic interactions, compared to those observed with vorinostat, were detected. This indicates that the synergistic effect is not limited to one class of HDACIs.
Finally, it should be noted that prior reports have indicated that Nrf2 is a target of acetylation. 37 Therefore it is possible that HDACIs may modulate acetylation status of Nrf2 and contribute to Nrf2 dependent antioxidant response.
The future study of Nrf2 acetylation status after treatment with HDACIs is of importance to further define the role of Nrf2 in resistance to HDACIs.
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